R&D channel feed

Gink­go joins Es­per­ovax to at­tempt RNA can­cer treat­ment — in a pill

3 years ago
Deals

While keep­ing eye on snap NASH OK, In­ven­ti­va tests out al­ter­na­tive PhI­II path

3 years ago
FDA+

Pfiz­er leads top-sell­ing phar­ma fore­cast — Eval­u­ate re­port

3 years ago
Pharma

Af­ter three-decade jour­ney, Geron sees new life in PhI­II da­ta on MDS drug, plots path to ap­proval

3 years ago

Hum­ming­bird and Synaf­fix agree to an­ti­body-drug con­ju­gate deal worth up to $150M

3 years ago
Deals

Cap­si­da makes $55M deal with Eli Lil­ly to de­vel­op gene ther­a­pies

3 years ago
Deals
Pharma

De­ci­phera re­vives hopes for Qin­lock with sub­group analy­sis, plots new PhI­II — but mar­ket re­ac­tion is mut­ed

3 years ago

Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

3 years ago

Ve­ra Ther­a­peu­tics sprints to PhI­II with treat­ment for rare kid­ney dis­ease

3 years ago

Pas­sage of FDA Mod­ern­iza­tion Act 2.0 clears the way to re­duce an­i­mal test­ing

3 years ago
Pharma

Fi­bro­sis start­up touts mid-stage NASH tri­al as it moves sole can­di­date for­ward

3 years ago

Every drug ap­proved in 2022: A year of few­er new prod­ucts, but gene ther­a­py firsts and new block­busters

3 years ago
Special
FDA+

Up­dat­ed: Off-the-shelf cell ther­a­py pi­o­neer Al­lo­gene re­cruits a Kite vet to run R&D

3 years ago
Bioregnum

FDA grants ap­peal for Arde­lyx chron­ic kid­ney dis­ease drug af­ter Ju­ly 2021 re­jec­tion

3 years ago
FDA+

Pfiz­er re­leas­es he­mo­phil­ia B PhI­II da­ta in chal­lenge to CSL's Hem­genix

3 years ago

FDA re­jects Ipsen rare-dis­ease drug, more da­ta and time need­ed to re­view

3 years ago
FDA+

Up­dat­ed: FDA clears first CD20xCD3 bis­pe­cif­ic, giv­ing Genen­tech leg up in a crowd­ed lym­phoma R&D field

3 years ago
Pharma
FDA+

Lex­i­con Phar­ma­ceu­ti­cals an­nounces mid-stage pain fail, blames dos­ing choice

3 years ago

Mor­phoSys CFO Sung Lee ex­its as shares suf­fer in mar­ket melt­down

3 years ago

Eli Lil­ly ties up 2022 by ex­pand­ing deal with bat­tered RNA-edit­ing biotech

3 years ago
Deals

Catch­ing up in mul­ti­ple myelo­ma, Pfiz­er taps ORIC for BC­MA com­bo study

3 years ago

FDA and EMA ac­cept Pfiz­er’s reg­u­la­to­ry sub­mis­sions for ul­cer­a­tive col­i­tis drug

3 years ago
FDA+

Zyner­ba cites 'triple­demic' for PhI­II de­lay of a cannabi­noid drug that's failed mul­ti­ple times

3 years ago

Every­one wants in on GLP-1: Pfiz­er dos­es first pa­tient in PhII tri­al for di­a­betes and obe­si­ty drug, pays So­sei $10M

3 years ago
First page Previous page 104105106107108109110 Next page Last page
A service from the Financial Times